We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
335 hedge funds and large institutions have $10.9B invested in Royalty Pharma in 2023 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 144 increasing their positions, 98 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,099% more call options, than puts
Call options by funds: $37.9M | Put options by funds: $3.16M
47% more repeat investments, than reductions
Existing positions increased: 144 | Existing positions reduced: 98
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
9% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 43
0.23% more ownership
Funds ownership: 67.87% → 68.1% (+0.23%)
0% less funds holding
Funds holding: 336 → 335 (-1)
8% less capital invested
Capital invested by funds: $11.8B → $10.9B (-$928M)
Holders
335
Holders Change
-1
Holders Change %
-0.3%
% of All Funds
5.34%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.16%
New
47
Increased
144
Reduced
98
Closed
43
Calls
$37.9M
Puts
$3.16M
Net Calls
+$34.7M
Net Calls Change
-$4.18M
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$85.4M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$66.7M |
| 3 |
Swedbank
Stockholm,
Sweden
|
+$45.1M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$44.3M |
| 5 |
Goldman Sachs
New York
|
+$40.1M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$153M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$124M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$80.5M |
| 4 |
Morgan Stanley
New York
|
-$70.3M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$27.8M |
